Bashir, Qaiser http://orcid.org/0000-0002-4086-6453
Milton, Denái R.
Popat, Uday R. http://orcid.org/0000-0002-7592-2224
Kebriaei, Partow
Hosing, Chitra
Khouri, Issa F.
Rezvani, Katayoun
Nieto, Yago
Oran, Betul
Srour, Samer A.
Saini, Neeraj Y.
Olson, Amanda L. http://orcid.org/0000-0002-1669-0355
Ahmed, Sairah http://orcid.org/0000-0001-7302-8299
Al-Atrash, Gheath
Rondon, Gabriela
Konopleva, Marina Y. http://orcid.org/0000-0002-9347-2212
Champlin, Richard E. http://orcid.org/0000-0002-4314-5037
Shpall, Elizabeth J.
Qazilbash, Muzaffar H. http://orcid.org/0000-0003-2876-2886
Pemmaraju, Naveen http://orcid.org/0000-0002-1670-6513
Article History
Received: 5 May 2021
Revised: 31 August 2021
Accepted: 21 September 2021
First Online: 11 October 2021
Competing interests
: QB has research funding from Acrotech and Stemline. QB served on advisory board of Purdue and Spectrum. MQ has research funding from Janssen, Bioline, Angiocrine, Amgen and Neximmune. SA has served on an advisory board and received research funding from Tessa Therapeutics and SeaGen. PK has research support from Amgen and Ziopharm; has served on advisory boards for Pfizer, Kite and Novartis; consulting fees from Jazz. MK has received grants and other from AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, and Forty-Seven. MK has received grants from Eli Lilly, Cellectis, Calithera, Ablynx, Agios, Ascentage, Astra Zeneca, Rafael Pharmaceutical and Sanofi. MK has received other from Amgen, Kisoji and Reata Pharmaceutical. MK holds US patent 7,795,305 B2, “CDDO-compounds and combination therapies thereof” with royalties paid to Reata Pharmaceutical, a patent Combination Therapy with a mutant IDH1 Inhibitor and a BCL-2 licensed to Eli Lilly, and patent 62/993,166 Combination of a MCL-1 Inhibitor And Midostaurin, Uses And Pharmaceutical Composition Thereof pending to Novartis. ES has received consultant fees and honoraria from Bayer HealthCare Pharmaceuticals, Novartis, Magenta and Adaptimmune. ES has received honoraria from Partner Therapeutics, Mesoblast and Axio. ES is the co-inventor on a provisional patent application owned by MD Anderson and licensed to Takeda. All other authors report no COI. This research was supported in part by the National Institutes of Health through the University of Texas MD Anderson Cancer Center’s Support Grant (CA016672).